factor VIII inhibitor

factor VIII inhibitor

IgG alloantibodies to factor VIIIc that inhibits coagulation, which occur in up to 50% of Pts with severe hemophilia A; factor VIII antibodies may arise spontaneously in inflammatory diseases–eg, SLE, rheumatoid arthritis, and ulcerative colitis, or with ↑ age, during post-partum period, or in drug reactions Mechanism Factor VIII inhibitor inactivates factor VIII by steric prevention of interaction of factor VIII with vWF, phospholipids, activated factors IX and X, and thombin, and by proteolysis. See Bethesda units, Factor VIII.
References in periodicals archive ?
For more information on factor VIII inhibitor plasmas, visit http://www.
The Bethesda test confirmed an elevated level of factor VIII inhibitor at 6.
Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity.
They are expressed as a Bethesda unit (BU) where one BU shows the amount of factor VIII inhibitor that can neutralize 50% of the activity of factor VIII in plasma after 2 hours incubation at 37[degrees]C.
3% and her factor VIII inhibitor level was 25 Bethesda units (measure of the level of inhibitor to coagulation factor VIII; equal to the amount of inhibitor in patient plasma that will inactivate 50% of factor VIII in an equal volume of normal plasma after a 2-h incubation period.
Factor VIII inhibitor formation in case 1 occurred 6 months after giving birth; underlying disorders were not identified in cases 2 or 3.
Clinical experience suggests that patients with a Factor VIII inhibitor titer of less than five Bethesda Units (B.
APTT based screening method for detection of factor VIII inhibitor, which is time and temperature dependent.
A diagnosis of acquired hemophilia A with Factor VIII inhibitor secondary to postpartum state was made.
Comparative thrombotic event incidence after infusion of recombinant factor VII a versus factor VIII inhibitor bypass activity.
The clinical use of factor VIIa in the treatment of factor VIII inhibitor patient.
Efficacy and safety of factor VIII inhibitor bypass activity (FEIBA) for long-term prophylaxis in patients with high-responding inhibitors.